Stockscreener 앱 받기
1.055
11.67%
-0.145
Allarity Therapeutics Inc 주식(ALLR)의 최신 뉴스
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration - Investing News Network
Allarity Therapeutics obtains CLIA lab certification By Investing.com - Investing.com Canada
Enterprise value to EBITDA forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Tranche Update on Allarity Therapeutics, Inc.'s Equity Buyback Plan announced on March 3, 2025. - marketscreener.com
Allarity Wins Key U.S. Patent for Stenoparib Diagnostic - TipRanks
Allarity Therapeutics (NASDAQ: ALLR) wins key DRP patent and secures shareholder backing - Stock Titan
Enterprise value to revenue forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Allarity receives U.S. patent for stenoparib diagnostic test - Investing.com
Allarity wins U.S. patent protection for stenoparib test into 2042 - Stock Titan
Price to earnings forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Price to book forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Allarity Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLR) - TradingView
ALLR Forecast — Price Target — Prediction for 2027 - TradingView
Is Allarity Therapeutics, Inc. (ALLR) outperforming other medical stocks this year? - MSN
Allarity Therapeutics Inc (ALLR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Allarity Therapeutics Showcases Phase 2 Stenoparib Trial Progress in Advanced Ovarian Cancer at ESMO 2026 - Minichart
Form 8K Allarity Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Allarity Therapeutics (NASDAQ: ALLR) showcases Phase 2 stenoparib ovarian cancer trial - Stock Titan
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 - Investing News Network
Allarity to present trial poster at cancer congress - Investing.com
Allarity to present trial poster at cancer congress By Investing.com - Investing.com Canada
Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire
Allarity Therapeutics Inc (ALLR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Allarity Therapeutics Inc (ALLR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allarity Therapeutics Inc (ALLR) Institutional Confidence - TradingKey
Allarity Therapeutics Inc (ALLR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Allarity Therapeutics Inc (ALLR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Allarity Therapeutics Inc (ALLR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Allarity Therapeutics Inc (ALLR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allarity Therapeutics Inc (ALLR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ALLR Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineNet Profit Margin - newsline.com
ALLR Maintained by Ascendiant Capital -- Price Target Raised to $10.25 - GuruFocus
ALLR Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Advances ContinueROA Comparison - dars.gov.et
Allarity Therapeutics (ALLR) Slides 5.3% as Stock Tests Critical Support LevelGap Fill Strategy - newsline.com
Are medical stocks lagging Allarity Therapeutics, Inc. (ALLR) this year? - MSN
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance
Amended and Restated Management Services Agreement Between Allarity Therapeutics, Inc. and Ljungaskog Consulting AB Effective June 1, 2026 - Minichart
Allarity Therapeutics Updates CEO Management and Compensation Agreement - TipRanks
Allarity (NASDAQ: ALLR) updates CEO pay and severance terms - Stock Titan
Number of shareholders of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
ALLR Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Advances PipelineGuidance Downgrade Alert - The Legal Advocate
ALLRAllarity Therapeutics Inc Options - Finviz
Allarity Therapeutics (ALLR) Faces Selling Pressure, Holds Above Key SupportVolatility Smile - thelegaladvocate.com
RKTO Stock Price and Chart — NASDAQ:RKTO - TradingView
Allarity Therapeutics (ALLR) Slides 4.8% in Session; Key Support Levels in FocusGEX Level - newsline.com
Allarity Therapeutics (ALLR) Surges 6.6% as Volume Picks Up, Testing Key ResistanceOption Breadth - The Legal Advocate
Allarity (ALLR) Posts Q1 2026 Earnings Beat — Here's What Drove ItPre-Announcement Alert - The Legal Advocate
Allarity (ALLR) Delivers Q1 2026 Beat — EPS $-0.17 vs $-0.22 ExpectedEarnings Season Preview - The Legal Advocate
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
Allarity Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Allarity Therapeutics Advances Stenoparib Development for Cancer Treatments and Strengthens Financial Position - Quiver Quantitative
Allarity Therapeutics Q1 net loss per share narrows - TradingView
U.S. VA backs trial of Allarity cancer drug for relapsed lung patients - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Allarity Therapeutics (ALLR) posts Q1 2026 loss but lifts cash with $20M notes - Stock Titan
Allarity Therapeutics (ALLR) CEO receives 200,000-share RSU equity grant - Stock Titan
Why Allarity (ALLR) Just Dropped -1.30% — What to Watch 2026-05-14Trade Entry - newser.com
1.60%
3.59%
자본화:
|
볼륨(24시간):